JPH10511961A - 高リポプロテイン血症、高トリグリセリド血症、高脂血症又は高コレステロール血症の治療又は予防のための、又は抗血液凝固処置のための医薬組成物の製造のための３，４−ジフェニル・クロマンの使用 - Google Patents

高リポプロテイン血症、高トリグリセリド血症、高脂血症又は高コレステロール血症の治療又は予防のための、又は抗血液凝固処置のための医薬組成物の製造のための３，４−ジフェニル・クロマンの使用

Info

Publication number: JPH10511961A
Authority: JP; Japan
Prior art keywords: compound; use according; patient; treatment; formula
Prior art date: 1995-01-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP8521377A

Other languages

English (en)

Japanese (ja)

Inventor

シャルミ，マイケル

コルスガールド，ナイエルス

ベイン，スティーブン

ヒョルトグルドハマー，バージット

ユーリクウェイス，ヤン

イー．ハート，チャールズ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-13

Filing date

1996-01-10

Publication date

1998-11-17

1996-01-10 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

1998-11-17 Publication of JPH10511961A publication Critical patent/JPH10511961A/ja

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 43
208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 33
230000002265 prevention Effects 0.000 title claims abstract description 23
208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 16
208000020346 hyperlipoproteinemia Diseases 0.000 title claims abstract description 16
208000006575 hypertriglyceridemia Diseases 0.000 title claims abstract description 16
238000004519 manufacturing process Methods 0.000 title claims abstract description 7
230000010100 anticoagulation Effects 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 title abstract description 10
VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title description 3
239000004305 biphenyl Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 50
150000003839 salts Chemical class 0.000 claims abstract description 28
125000003545 alkoxy group Chemical group 0.000 claims abstract description 20
206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 14
125000000217 alkyl group Chemical group 0.000 claims abstract description 14
208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 14
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
239000001257 hydrogen Substances 0.000 claims abstract description 14
125000001302 tertiary amino group Chemical group 0.000 claims abstract description 11
239000003146 anticoagulant agent Substances 0.000 claims abstract description 7
229940127219 anticoagulant drug Drugs 0.000 claims abstract description 7
229910052736 halogen Inorganic materials 0.000 claims abstract description 6
150000002367 halogens Chemical group 0.000 claims abstract description 6
150000002431 hydrogen Chemical group 0.000 claims abstract description 6
238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
201000001320 Atherosclerosis Diseases 0.000 claims description 21
238000000034 method Methods 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 12
229960003327 ormeloxifene Drugs 0.000 claims description 10
238000009472 formulation Methods 0.000 claims description 8
206010011091 Coronary artery thrombosis Diseases 0.000 claims description 7
208000002528 coronary thrombosis Diseases 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 6
238000011321 prophylaxis Methods 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
239000007943 implant Substances 0.000 claims description 3
230000023555 blood coagulation Effects 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
230000003287 optical effect Effects 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 4
206010021024 Hypolipidaemia Diseases 0.000 claims 2
206010020961 Hypocholesterolaemia Diseases 0.000 claims 1
206010021128 Hypotriglyceridaemia Diseases 0.000 claims 1
208000026621 hypolipoproteinemia Diseases 0.000 claims 1
230000035851 hypotriglyceridemia Effects 0.000 claims 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 35
230000000694 effects Effects 0.000 description 19
XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 15
-1 beta-pyrrolidinoethoxy Chemical group 0.000 description 14
241001465754 Metazoa Species 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 9
235000012000 cholesterol Nutrition 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
229940011871 estrogen Drugs 0.000 description 6
239000000262 estrogen Substances 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
108010028554 LDL Cholesterol Proteins 0.000 description 5
238000008214 LDL Cholesterol Methods 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
230000009467 reduction Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000002792 vascular Effects 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 3
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
241000288906 Primates Species 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
238000010171 animal model Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
229960002568 ethinylestradiol Drugs 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
230000002980 postoperative effect Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
108010023302 HDL Cholesterol Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
238000011161 development Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
238000011587 new zealand white rabbit Methods 0.000 description 2
238000009806 oophorectomy Methods 0.000 description 2
238000003305 oral gavage Methods 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000001603 reducing effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
PPXSXRTVWVIXJR-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-chromene Chemical compound C1CCOC2=CC(OC)=CC=C21 PPXSXRTVWVIXJR-UHFFFAOYSA-N 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
201000000057 Coronary Stenosis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000005961 cardioprotection Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000006372 lipid accumulation Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960001207 micronized progesterone Drugs 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
210000004623 platelet-rich plasma Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000004224 protection Effects 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000011421 subcutaneous treatment Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrane Compounds (AREA)

JP8521377A 1995-01-13 1996-01-10 高リポプロテイン血症、高トリグリセリド血症、高脂血症又は高コレステロール血症の治療又は予防のための、又は抗血液凝固処置のための医薬組成物の製造のための３，４−ジフェニル・クロマンの使用 Pending JPH10511961A (ja)

Applications Claiming Priority (13)

Application Number	Priority Date	Filing Date	Title
DK4195		1995-01-13
DK0043/95		1995-01-13
DK4395		1995-01-13
DK0041/95		1995-01-13
DK0069/95		1995-01-20
DK6995		1995-01-20
DK0777/95		1995-06-30
DK0767/95		1995-06-30
DK76795		1995-06-30
DK0766/95		1995-06-30
DK76695		1995-06-30
DK77795		1995-06-30
PCT/DK1996/000014 WO1996021443A1 (fr)	1995-01-13	1996-01-10	Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique de traitement ou de prophylaxie de l'hyperlipoproteinemie, de l'hypertriglyceridemie, de l'hyperlipidemie, de l'hypercholesterolemie, de l'arteriosclerose, ou dans un traitement anticoagulant

Publications (1)

Publication Number	Publication Date
JPH10511961A true JPH10511961A (ja)	1998-11-17

Family

ID=27545138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8521377A Pending JPH10511961A (ja)	1995-01-13	1996-01-10	高リポプロテイン血症、高トリグリセリド血症、高脂血症又は高コレステロール血症の治療又は予防のための、又は抗血液凝固処置のための医薬組成物の製造のための３，４−ジフェニル・クロマンの使用

Country Status (11)

Country	Link
EP (1)	EP0804189A1 (fr)
JP (1)	JPH10511961A (fr)
CN (1)	CN1168098A (fr)
AU (1)	AU4329296A (fr)
BR (1)	BR9606890A (fr)
CA (1)	CA2208859A1 (fr)
CZ (1)	CZ212397A3 (fr)
HU (1)	HUP9800521A3 (fr)
IL (1)	IL116745A (fr)
NO (1)	NO973241L (fr)
WO (1)	WO1996021443A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002517433A (ja) *	1998-06-11	2002-06-18	アンドルシェルシュ・インコーポレイテッド	選択的エストロゲン受容体モジュレーターと性ステロイド前駆体の組合せの医学的使用
US8389548B2 (en)	1998-06-11	2013-03-05	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5407955A (en) *	1994-02-18	1995-04-18	Eli Lilly And Company	Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US6069175A (en) *	1996-11-15	2000-05-30	Pfizer Inc.	Estrogen agonist/antagonists treatment of atherosclerosis
AU3023999A (en) *	1998-03-20	1999-10-18	Novo Nordisk A/S	Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for lowering plasma levels of lp(a) in a human or sub-human primate
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
US8080675B2 (en)	2004-09-21	2011-12-20	Marshall Edwards, Inc.	Chroman derivatives, medicaments and use in therapy
CA2581316C (fr)	2004-09-21	2013-09-10	Novogen Research Pty Ltd	Derives de chromane substitues, medicaments et utilisation a des fins therapeutiques
EP2635273B1 (fr)	2010-11-01	2020-01-08	MEI Pharma, Inc.	Compositions d'isoflavonoïdes et méthodes de traitement du cancer
MX368063B (es)	2014-02-07	2019-09-18	Novogen ltd	Compuestos de benzopirano funcionalizados y uso de los mismos.
CN116139125A (zh)	2015-02-02	2023-05-23	梅制药公司	联合治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1543749A1 (de) *	1966-02-16	1969-12-11	Merck Ag E	Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5407955A (en) *	1994-02-18	1995-04-18	Eli Lilly And Company	Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

1996
- 1996-01-10 EP EP96900095A patent/EP0804189A1/fr not_active Withdrawn
- 1996-01-10 HU HU9800521A patent/HUP9800521A3/hu unknown
- 1996-01-10 WO PCT/DK1996/000014 patent/WO1996021443A1/fr not_active Ceased
- 1996-01-10 BR BR9606890A patent/BR9606890A/pt not_active Application Discontinuation
- 1996-01-10 CA CA002208859A patent/CA2208859A1/fr not_active Abandoned
- 1996-01-10 AU AU43292/96A patent/AU4329296A/en not_active Abandoned
- 1996-01-10 JP JP8521377A patent/JPH10511961A/ja active Pending
- 1996-01-10 CN CN96191417A patent/CN1168098A/zh active Pending
- 1996-01-10 CZ CZ972123A patent/CZ212397A3/cs unknown
- 1996-01-12 IL IL11674596A patent/IL116745A/xx not_active IP Right Cessation
1997
- 1997-07-11 NO NO973241A patent/NO973241L/no unknown

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002517433A (ja) *	1998-06-11	2002-06-18	アンドルシェルシュ・インコーポレイテッド	選択的エストロゲン受容体モジュレーターと性ステロイド前駆体の組合せの医学的使用
US7429576B2 (en)	1998-06-11	2008-09-30	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7884092B2 (en)	1998-06-11	2011-02-08	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7943603B2 (en)	1998-06-11	2011-05-17	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8188066B2 (en)	1998-06-11	2012-05-29	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8389548B2 (en)	1998-06-11	2013-03-05	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number	Publication date
CZ212397A3 (en)	1997-11-12
HUP9800521A2 (hu)	1998-12-28
BR9606890A (pt)	1997-10-28
IL116745A (en)	1999-12-22
HUP9800521A3 (en)	1999-12-28
AU4329296A (en)	1996-07-31
MX9705214A (es)	1997-10-31
IL116745A0 (en)	1996-05-14
EP0804189A1 (fr)	1997-11-05
NO973241D0 (no)	1997-07-11
CA2208859A1 (fr)	1996-07-18
NO973241L (no)	1997-07-11
WO1996021443A1 (fr)	1996-07-18
CN1168098A (zh)	1997-12-17

Publication	Publication Date	Title
KR100263009B1 (ko)	2000-08-01	3,4-디아릴크로만을 포함하는 뼈 손실 억제에 유용한 조성물
JPH10511962A (ja)	1998-11-17	婦人科疾患の治療または予防用の医薬組成物の製造への３，４−ジフェニルクロマンの使用
JP2000506508A (ja)	2000-05-30	良性前立腺肥大の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
JPH10511961A (ja)	1998-11-17	高リポプロテイン血症、高トリグリセリド血症、高脂血症又は高コレステロール血症の治療又は予防のための、又は抗血液凝固処置のための医薬組成物の製造のための３，４−ジフェニル・クロマンの使用
JP2000506507A (ja)	2000-05-30	前立腺癌の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
JP2000506505A (ja)	2000-05-30	閉経期の症状の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
AU722355B2 (en)	2000-07-27	New hormonal medicaments and their use for the correction of oestrogenic deficiencies
JP2001500101A (ja)	2001-01-09	乳癌の治療及び予防のための医薬組成物の製造のためのセントクロマンのｌ―鏡像異性体の使用
JPH10511960A (ja)	1998-11-17	特発性の又は生理学的な女性化乳房の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
US5886021A (en)	1999-03-23	Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
JPH10512270A (ja)	1998-11-24	肥満の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
WO1998033499A1 (fr)	1998-08-06	Utilisation de chromanes de 3,4-diphenyle pour la fabrication d'une composition pharmaceutique destinee a augmenter la libido chez les femmes en phase de post-menopause
JP2002534469A (ja)	2002-10-15	エストロゲン及びデルタ−ゴナジエン−２１−オール−３，２０−ジオンの使用
US5780502A (en)	1998-07-14	Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
KR19980701382A (ko)	1998-05-15	고리포단백혈증, 고트리글리세리드혈증, 고지방혈증 또는 고콜레스테롤혈증, 또는 동맥경화증의 치료 또는 예방용 또는 항응고제 치료용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용
MXPA97005214A (en)	1998-07-03	Use of the 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arterioesclerosis or for anti-treatment
JP2000514441A (ja)	2000-10-31	月経前症候群の１又は複数の症状を抑制するための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
MXPA97005379A (en)	1998-07-03	Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad
WO1999048497A1 (fr)	1999-09-30	UTILISATION DE 3,4-DIPHENYLCHROMANNES POUR LA FABRICATION D'UNE COMPOSITION PHARMACEUTIQUE DESTINEE A LA REDUCTION DES CONCENTRATIONS PLASMATIQUES DE Lp(a) CHEZ L'HOMME OU CHEZ DES PRIMATES
KR19980701383A (ko)	1998-05-15	부인병 질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia)
MXPA97005219A (en)		Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi